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Summary.-Extensive experience with isotransplants of 27 different tumours
(leukaemias, sarcomata, carcinomata), allofstrictly spontaneousorigininlaboratory
bred mice of low cancer strains CBA/Ht and WHT/Ht, has revealed no evidence
of tumour immunogenicity. Of approximately 20,000 maintenance transplants,
none failed and none regressed; of almost 10,000 carefully observed tumours arising
from small or minimal inocula of tumour cells, none spontaneously regressed.
The number of injected viable tumour cells required to give a 50% probability of
successful transplantation (the TD50) ranged from 1 cell to > 10,000 cells among
the 27 tumours; high TD50 values, which were dramatically reduced by various
procedures having noimmunological significance, did notsignifyactive" resistance "
of the hosts. In the case of all of 7 randomly selected tumours, prior "immuniza-
tion " of recipients with homologous lethally irradiated cells increased their tumour
receptivity.
Several experiments using various tumours failed to give evidence that immunity
could be non-specifically induced or that a massive preponderance of lymphocytes
from specifically sensitized mice could inhibit tumour transplantation or growth
in vivo; no trace of " resistance " to tumour was adopted by isogeneic recipients
of lymphocytes from regional nodes of tumour bearers. A limited review of the
recent literature on tumour immunity shows that practically all the animal data
presented in support of a general theory of tumour immunogenicity or to provide
a basis for active clinical immunotherapy have been obtained from transplanted
tumour systems which entail artefactual immunity associated with viral or chemical
induction of the tumours or their allogeneic transplantation. It is suggested that
isotransplants of spontaneously arising tumours are the only appropriate models
of human cancer and that any genuine rapport between the animal laboratory and
the clinic requires their exclusive use.
WE REPORT here a considerable volume
of data concerning the transplantation
characteristics of a large number and
variety of murine tumours having the
distinction that they were all of strictly
spontaneous origin in low cancer strain
mice. The data, collected over many
years of experimentation, have some
additional claim to uniqueness from the
exceptionally uniform conditions under
which the information was obtained: the
breeding colonies of inbred mice have
been managed in every detail by one of us
16
(A.S.W.); all other technical procedures
have been carried out personally by the
authors without additional assistance; to
validate comparison of data between
different tumours and from time to time
over long periods of any one tumour's
history, the routine technical procedures
have not been varied in any significant
particular; and, finally, a detailed record
has been kept of the fate of every mouse
used in every experiment, permitting the
retrospective analysis of our experience
which we are to report.H. B. HEWITT, E. R. BLAKE AND A. S. WALDER
A feature of our experiments, required
by the studies of tumour radiobiology and
of metastasis to which they contributed,
was that all transplantations (except
maintenance and preparatory passages)
were made quantitatively using counted
tumour cell suspensions and mostly em-
ploying several uniformly injected sites
per mouse. Since the success of such
grafts is determined by some function
relating the size of the inoculum and the
receptivity of the injectee, it is clear that
our collected data are in some way expres-
sive of the host/tumour relationship; they
deserve serious consideration in the con-
text of tumour immunology. Whilst that
topic has certainly not instigated our
studies, the interpretation of our experi-
mental results has required continual
alertness to the possible complicity of an
immunological response of the hosts. Our
vigilance was stimulated by the prevalent
theory that neoantigens necessarilyemerge
at malignant transformation, implying
that potential tumour immunogenicity is
intrinsic to tumour biology. From an early
satisfaction that we had been fortunate to
escape complications from this ingredient,
we have progressed to our present con-
viction thatourexperience conflicts abso-
lutely with the broad assertion that
tumour immunogenicity is a common and
detectable feature of spontaneous cancer.
We believe that this conflict arises out of
our deliberate and exclusive use of
tumours of spontaneous origin isogeneic-
ally transplanted within our own inbred
mouse colonies.
Our purpose here is to present features
of our broad experience which appear
significant in the context of tumour
immunology, as presented by the reports
of host response against experimental
tumours and in respect of its relevance to
human cancer.
Consideration of our experience has
compelled us to examine more closely the
evidential basis of the concept of tumour
immunogenicity as derived from clinical
observation and, further, to examine
critically the status of the profusion of
animal tumour data that now underpins
the fragile structure of clinical impression.
Our object will be to enquire whether the
apparent singularity of our findings can
be ascribed to the category of tumour we
have exclusively studied. We shall initiate
this enquiry here and pursue it more
pointedly in the Discussion ofour findings.
A concept that the course of clinical
cancer is the resultant of interaction
between tumour growth potential and
some active and inherent host defence
against it has prevailed for over one and a
half centuries (see Report, 1806). Per-
petuation of the tradition is displayed in
contemporary case reports, which very
commonly attach immunological inter-
pretations to unexpectedly favourable (or
unfavourable) developments in the course
of cancer, with careless disregard of the
evidence required to validate such expla-
nations for consoling (or disappointing)
prognosis. A classic requirement for de-
monstration of immunity is some facility
for detecting a differential response to
sequential applications of an " antigen ".
The facility is not provided by patients
with established cancer, who have been in
continuous contact with their cancers
since their inception, usually many years
previously (Collins, Loeffler and Tivey,
1956). It is clear that very subtle
deviations from classic standards of evi-
dence are required if effective immuno-
logical exertion is to be perceived in such
circumstances. Indeed, it is significant
that research in this field is currently
sustained by a theory which entails the
assumption offailure, relative or absolute,
of an active host defence against pro-
gression of the disease which was never
demonstrable.
The recent surge of publications on
tumour immunity (typically represented
in one leading cancer journal by an
increase in the proportion ofspace devoted
to them from 4% in 1966, to 13% in 1971,
on to 27% in the first half of 1974) does
not, in our view, substantiate any general
theory of active defence against the
clinical disease. In vitro demonstrations
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of tumour-specific or associated antigens
or of various interactions between tumour
cells, inflammatory cells and humoral
factors, do not constitute evidence of
effective imrnmunogenicity; it has yet to be
shown that they are more than epi-
phenomena or that they betoken in vivo
influences effective in restraining the
disease (Currie, 1974).
Animal tumour models are certainly
required if evidence for induced resistance
against cancer is to be provided in a form
that is consistent with classic immuno-
logical precepts; that is, a differential
response to challenge with viable cancer
cells has to be demonstrated between
normal animals and those that have been
conditioned by contact with specific
challenge material. There is no doubt that
inductionofimmunity againsttumours has
been so demonstrated with undiminished
frequency from the beginning of experi-
mental cancer research. The telling
question is whether the transplanted
tumour systems that have been and are
being used are valid models of the natural
disease; they must certainly be dis-
qualified from this role if the immune
reactivity displayed can be reasonably
attributed to one or other of a number of
laboratory artefacts that can be inferred
from a tumour's origin or conditions of
transplantation. Since the simultaneous
exertion ofnatural and artefactual tumour
immunity presents the daunting problem
of their distinction and separate measure-
ment, the ineligibility of a system has to
be pronounced from circumstantial evi-
dence alone.
The status ofthe systems we have used
must be considered in relation to the
several categories into which animal
tumour systems can be classified:
I. Allografted tumours.
2. Virus-induced tumours.
3. Chemically induced tumours.
4. Spontaneous tumours.
All allografted ttumours entail arte-
factual immunity; they include not only
old tumours of unspecified genetic origin
but also systems in which transplantation
is nominally isogeneic, but in which the
long history of a tumour and particularly
its origin in some other laboratory, make
it highly probable that genetic divergence
has taken place between the recipients
used and the substrain of origin; even
transplants into F1 hybrid mice are not
strictly isogeneic. In the case of tumours
of categories 2-4, our discussion of their
eligibility as models will assume strictly
isogeneic transplantation. Tumours in-
duced by a specified virus are well known
to share a membrane antigen and a vast
literature testifies to their, often strong,
immunogenicity. What we must acknow-
ledge here is that virus-induced tumours
are rarities and that there is no reason to
suppose that the generality of tumours are
so induced (Rous, 1965); certainly no
human malignancy, with the possibly
impending exception of Burkitt's disease,
has been proved to be of viral causation.
Chemically induced (C-I) tumours are
usually immunogenic; indeed, the earliest
reports of this peculiarity (Gross, 1943;
Foley, 1953; Prehn and Main, 1957)
presented the finding as a discovery.
Although a special status for C-I tumours
on this account is commonly refused, all
comparisons that have been made have
revealed a degree of immunogenicity in
C-I tumours which was rarely, if ever,
encountered in tumours of spontaneous
origin (Prehn and Main, 1957; Marchant,
1968; Klein, 1970; Suit and Kastelan,
1970). The immunogenicity of C-I
tumours is associated with the immuno-
suppressive activity of the powerful carci-
nogenic agents almost invariably used in
the laboratory for tumour induction
(Prehn, 1963; Stjernsward, 1965; Beren-
baum, 1964, Szakal and Hanna, 1972).
Prehn (1963) considered that the immuno-
suppressive action of chemical carcinogens
might well be an essential component of
the mechanism of their carcinogenicity.
The above abbreviated review is, we
believe, sufficient to deny C-I tumours any
status as acceptable models of naturally
".d43H. B. HEWITT, E. R. BLAKE AND A. S. WALDER
occurring malignant disease in man, at
least in respect of considerations of
tumour immunogenicity.
It remains for us to define "spontan-
eous " murine tumours a priori as those
that arise in otherwise normal low-cancer
strain mice which have received no treat-
ment which is calculated or liable to
induce cancer. It is to this category that
our tumours belong and to which, in
respect of their origin, practically all
human cancers belong; it is also the
category which includes those tumours
least likely to entail artefactual immunity.
It is true that inadvertent exposure of
man to chemical carcinogens or cocarci-
nogens may be implicated in the aetiology
of, for example, bronchial carcinoma.
But these inducing agencies are neither
powerful nor immunosuppressive carci-
nogens. In any case, Prehn (1963) has
shown that tumours arising a relatively
long time after initial application ofcarci-
nogen are the least likely to display
immunogenicity.
Following the above considerations,
we conclude that evidence from animal
tumours ofspontaneous origin is peculiarly
pertinent to the questions whether clinical
tumours are commonly immunogenic and
whether trials of active immunotherapy
are justifiable by laboratory findings.
Since spontaneous tumours are readily
available, even from relatively small
animal colonies, and as no experimental
procedure is required for their production,
some explanation is required for the
evident discrimination against them for
studies in tumour immunology. Perusal of
80 randomly selected papers on this topic
published during 1970 revealed that in
93% of cases the less eligible categories of
tumour had been used in the experiments
reported. One very recent volume of a
leading cancer journal reports immuno-
logical studies in which a total of 17
animal tumour systems were employed:
15 were chemically induced; the remaining
2 were virus induced.
We present our accumulated experi-
ence in the hope that it may encourage a
fair view of the frequency of tumour
immunogenicity, of which we have been
long deprived by overzealous preoccupa-
tion of researchers with what may prove
to be seductive artefacts. Considerations
pertinent to particular parts of our pres-
entation will be discussed where they are
relevant. Our Discussion will deal more
incisively with the application of experi-
mental findings to clinical tumour im-
munology.
ANIMAL FACILITY
For 20 years we have maintained
closed conventional colonies of inbred
mouse strains CBA/Ht and WHT/Ht.
Breeding has been strictly by brother-
sister mating within single litters, and
replacement of breeders has been by
littermates distinguished only by their
normality ofbody weight and membership
of a litter of normal size. Stock mice for
experimental use are mustered randomly
from the breeding colony at the time of
weaning. An implication ofthis routine is
that the mice contributing to any single
experiment are representatives ofmultiple
sublines separated over an indefinite
number ofgenerations. However, regular
testing by reciprocal skin grafts between
sublined mice has failed to reveal evidence
of heterogeneity. Arbitrary designation
of sublines is practised from time to time
to permit a retrospective search for
subline differences of quantitative tumour
receptivity, should such differences be
suspected among the mice contributing to
an experiment; all such searches have
been unrevealing. The incidence of inter-
current disease in mice under experiment
has been rare (certainly under 1%).
DETECTION AND TRANSPLANTATION OF
SPONTANEOUSLY ARISING MALIGNANT
DISEASE
Neither the WHT nor the CBA strain
of mouse has a high incidence of sponta-
neous tumours in any site, and both can
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therefore be described as " low cancer
strains "; neither strain has had any
known association with an oncogenic
virus, although a colony of C3H mice
(harbouring the mouse mammary tumour
agent) has been housed in a separate part
of the animal house during the past five
years.
Animal house staff are well trained to
observe evidence of sickness or tumours in
mice during routine changing of cages.
Sick or tumour-bearing mice are killed and
dissected under fully aseptic conditions so
that immediate, sterile transplantation of
any malignancy can be undertaken. Most
of our tumours have arisen in breeding or
ex-breeder mice. We suspect that the
opportunity to perpetuate spontaneous
tumours for use as experimental facilities
mav often be lost because animal house
staff are not made aware of their value or
because elective conditions for their trans-
plantation are not immediately avail-
able.
All of 50 or so confirmed malignancies
that we have encountered have been
readily transplantable within their strain
of origin at a first passage. Some, as we
shall describe, have been quantitatively
transplanted at the first passage. Reports
of a low rate of isogeneic transplantability
of primary, spontaneous, malignant
tumours would seem to us to indicate
either some inadequacy of technique, or
unsuspected genetic heterogeneity within
the nominally homozygous strain used.
It is important in an immunological
context to state that the tumours we
selected for further study (Table I) were
recommended by histological or other
characteristics relevant to our interests at
the time they became available; none were
rejected because offeatures suggestive oftheir
immunogenicity. Attempts to evoke a
rejection response by immunization of
recipients, to be described, were under-
taken only after tumours had come into
use, our purpose then being to identify any
possible contribution of host resistance to
the results of experiments relating to
tumour radiobiology or metastasis.
SERIAL TRANSPLANTATION OF TUMOURS:
SUCCESS RATE; REGRESSION RATE
Over 40 different tumours of sponta-
neous origin have been serially trans-
planted using single inocula and only 2
mice per passage. Solid tumours were
transplanted s.c. using minced tumour,
ascitic tumours i.p. using neat or diluted
ascites fluid, and non-ascitic leukaemias
i.p. using washings of minced liver infil-
trate. The number of serial passages
completed for the different tumours ranges
from 3 to 590. Some assurance of the
scrupulousness ofourtransplantation tech-
niques is given by the fact that inter-
contamination of tumours has never oc-
curred, although many share a common
mouse strain and can be transplanted with
less than 10 cells (in the case ofleukaemias,
transplantation can be effected even by
contamination through dermal abrasions
-Hewitt, 1961). In approximately 20,000
-such routine transplantations, we have
enountered only 2 failures to take and not a
single instance of spontaneous regression.
The failures to take involved 2 WHT
mice which were found to be totally
resistant to the take of several tumours of
origin in this strain; they wNere evidently
the sole representatives of an abortive
subline of WHT carrying homozygous
representation of a mutation at a major
histocompatibility locus. Since our ex-
perience for some tumours extends over 10
years, it is clear that " genetic drift "
within the inbred colonies of mice used
has only a very small probability of con-
tributing artefactual tumour immunity to
a transplant system.
A survey of the current literature will
reveal that our very large experience of
tumours of spontaneous origin, in respect
oftheir failure to exhibit signs ofimmuno-
genicity, contrasts strikingly with reported
experience using many widely employed
tumours of different status. For example,
intradermal implants of the chemically
induced tumour, Sarcoma 1, into mice of
the strain of origin (A/Jax) yielded 26%
offailures to take and 3900 ofspontaneous
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regressions (Dunham and Waymouth,
1972-73).
QUANTITATIVE TRANSPLANTATION OF
TUMOURS (TD50 ASSAYS)
Technical procedures
Many of our experiments have been
designed to measure the proportion of
malignant cells retaining their reproduc-
tive integrity after exposure of tumour-
bearing or leukaemic mice to specified
doses of irradiation in vivo. Our measure-
ments of cell survival have been by the
use of transplantation bioassays of single-
cell suspensions prepared from leukaemia
infiltrates or solid tumours by methods
described previously in detail (Hewitt,
1958; 1966). The density of morpho-
logically intact tumour cells is determined
by counting in a haemacytometer using
phase-contrast microscopy; in the case of
most tumours, experience permits a ready
distinction of malignant cells from con-
taminating normal tissue cells; several
tumours can be actually identified by the
peculiar morphology of their separated
cells. Counted suspensions are serially
diluted to provide a range of mean
inoculum sizes expressed as number of
apparently viable tumour cells per in-
oculum. Selected dilutions of counted cell
suspensions are injected subcutaneously
into groups of at least 4 mice, each mouse
receiving 4 well-separated inocula in
ventral sites. Mice are palpated every 2
days and a record is kept ofthe appearance
of tumours in the injected sites; with
experience, tumours can be palpated when
they are only a few mm3 in volume.
Leukaemia cell suspensions are similarly
assayed but by the injection of single i.p.
inocula into uniformly injected groups of
6 or more mice, positive takes being regis-
tered by the development of signs of
leukaemic disease; all such mice, as well
as mice surviving to the end of the
observation period, are killed and ex-
amined internally to confirm the condition
recorded.
Ideally, the data of a completed assay
show a progressive fall from 100% takes
for the largest inocula to zero for the
smallest. In any case, the number of cells
required for 50% takes (the TD50) is
obtained by graphical or calculated inter-
polation, or from a specially devised
computer programme which provides also
the confidence limits of the TD50 value
(Porter, Hewitt and Blake, 1973); these
differentmethodsdidnotyieldsignificantly
different values for a TD50. The above
publication discusses in detail considera-
tions relating to the distribution of data
within an assay.
As we shall show later, the use of 4
sites per mouse in the assays of solid
tumour cells provides for an analysis of
our data which can distinguish possible
heterogeneity of the recipient mice in
respect oftheir relative systemic ability to
" resist " inocula of a limited number of
isogeneic tumour cells.
We wouldemphasise here that,for almost
10,000 sites developing tumours in assays of
various irradiated or unirradiated cell
suspensions, we have never observed sponta-
neous regression of a tumour after its
progressive growth had been indubitably
established. We need to state this minor
condition because large inocula even of
lethally irradiated tumour cells commonly
give rise to evanescent palpable nodules,
which can reasonably be attributed to
residual abortive proliferation and giant
cell formation.
Range of TD50 values for different tumours
of spontaneous origin
It will be seen from Table I that TD50
values for 27 different tumours range
from close to 1-0 for several lymphoid
tumours to over 18,000 for an osteosar-
coma. For some of the tumours only one
assay was done; for more than half the
tumours several assays were done during
the tumour's history, as required by our
experiments, and in those cases we have
indicated the variability of values by
giving in brackets limits defined by one
standard deviation calculated from the
log TD50 values observed. In the case of
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TABLE L.-Results ofIsogeneic Transplantation Assays of 27
ofSpontaneous Origin
Tumour
Reticulum cell sarcoma
Leukaemia " Th "
Ascites Leukaemia I
Ascites Leukaemia I
Leukaemia " SI "I
Lymphosarcoma
Leukaemia "Sp" II
Leukaemia "S1 "II
Carcinoma "M.T. "
Sq. Carcinoma "D"
Fibrosarcoma
Sarcoma " Ax"
Endothelioma II
Sq. Carcinoma I
Sarcoma "F"
Sarcoma "F"
Sarcoma "Ch"
Sarcoma S "
Osteosarcoma I
Fibrosarcoma
Sq. Carcinoma " G"
Carcinoma " N-C"
Endothelioma I
Carcinoma "Cr"
Carcinoma "Rh"
Carcinoma "N.T."
Adenocarcinoma " NMT"
Sq. Carcinoma II
Osteosarcoma II
Route
I.P.
I.P.
I.P.
S.C.
I.P.
I.P.
I.P.
I.P.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
S.C.
No. of
assays
14
4
1
9
1
3
1
5
11
1
3
1
1
9
12
1
1
2
2
4
1
1
1
1
21
1
1
4
Serial
passage(s)
1
35-231
33-82
144
76-325
1
38-114
20
5-350
14-289
123
10-26
11
61
35-84
170-488
4
51
164-170
138-208
14-38
19
3
1
1
22-101
9
13
4-62
Murine Tumours
TD50 (cells)t
1-2
1-4 (0 7-2 2.8) 1-48 (0 7-3 4) 195
2-0 (0-1-3-4)
4 0
5-8 (2-16)
9
10 - 6 (4 8-23)
14-4 (9-8-21)
17
25 (5-9-102)
26
32
56 (31-103)
263 (119-579)
79
100
313 (146-671)
416 (280-630)
1000 (440-2400)
1300
1700
1800
2950
3900 (1940-7850)
10,000
>1 1,000
17,000 (11,000-27,000)
* In later references to the tumours, the serial number will be bracketed after the name. t The value given for multiple assays is the log mean followed by limits representing ± 1 standard devia- tion.
tumours for which 3 or more values were
available, it was possible to seek a trend:
for WHT Sq. Carcinoma " G " (19) there
was a significant fall from 3020 to 398
between the 14th and 38th serial passages;
for WHT Sarcoma " Ax " (11) a definite
rise was seen from 5 in the 10th to 78 in the
26th passage; in the case of our oldest
tumour, CBA Sarcoma " F " (14), the log
mean value of 12 assays done between the
150th and 488th passages was 5 times
greater than the mean for 9 earlier assays,
this difference being highly significant.
For the remaining tumours repeatedly
assayed, a remarkable stability was ob-
served in the TD50 value over long periods
of serial study (CBA Leukaemia " Th"
(2)-12 years; WHT Sq. Carcinoma " D"
(9) 9 years; CBA Carcinoma " N.T."
(24)-4 years). The exceptionally large
number of assays for Tumour 24 reflects
an intensive study we made ofthis tumour
to explore the significance of its high TD50 value-the highest one we had
observed when that study was initiated.
Four tumours (1, 5, 22 and 23) were
assayed in the course of their first trans-
plantation from the animal in which they
arose, thus providing what may be unique information. It will be noted that the 2
lymphomata (1 and 5) gave typically low
values, one being the lowest in the table;
the 2 carcinomata (22 and 23) gave values
which were typically within our general experience. These assays of primary tumours were undertaken to examine a
suggestion of Smithers (1962) that the
malignant potential does not reside in
individual cells, implying that such very low TD50 values as we have reported signify transformation of the primary malignant condition to a state of "auto-
Serial*
no.
1
2
3
3
4
5
6
7
8
9
10
11
12
13
14
14
15
16
17
18
19
20
21
22
23
24
25
26
27
Mouse
strain
WHT
CBA
WHT
WHT
CBA
WHT
CBA
CBA
WHT
WHT
WHT
WIIT
WHT
CBA
CBA
CBA
WHT
CBA
WHT
CBA
WHT
WHT
WHT
CBA
WHT
CBA
WHT
CBA
WHT
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nomy " as the result of serial transplanta-
tion; his implication is that tumours such
as ours are not models of the natural
disease in man. Our unique evidence does
not at all support this view; a single
transplantation of a small mouse tumour
represents as short a tumour history as
that of a large primary clinical tumour.
In the next section we shall give our
reasons for concluding that high TD50
values have no immunological significance.
Significance of high TD50 values
Table I shows that successful trans-
plantation of many tumours requires the
injection of a relatively large number of
tumour cells that can be assumed to be
viable; for example, 100% takes of WlHT
Osteosarcoma II (27) requires about
70,000 cells. The temptation is to assume
that the recipient has " resisted " a large
number of the malignant cells and that its
" resistance " has been overwhelmed by
the size of the inoculum. Indeed, an
immunological interpretation has been
suggested for the failure of large auto-
grafts of tumour cells in man (Southam
and Brunschwig, 1961). However, the
inability of an inoculum of tumour cells to
establish itself as a progressively growing
tumour does not necessarily imply any
active exertion of the host against the
tumour, and the use of the term " resis-
tance " is here unsuitable in its unfounded
implication of such active exertion. An
equally eligible description is that some
condition required for establishment ofthe
graft is deficient.
To explore the significance of high TD50
values, we have carried out many experi-
ments designed to alter significantly the
characteristic value for a tumour. None
ofour procedures has raised it; many have
reduced it. An almost universal finding
has been that addition of lethally irra-
diated (LI) homologous cells to limited
inocula of viable tumour cells has very
significantly reduced the TD50. Table II
shows for several tumours the results of
parallel assays of viable tumour cells
injected with or without a large pre-
ponderance ofhomologous LI cells. It will
be seen that the additive almost invariably
reduced the TD50 to single figure values;
in general, the magnitude of the effect, as
represented by the factor difference be-
tween the TD50 values under the two
conditions, increases with the size of the
control TD50. This phenomenon, which is
a particular presentation of the Revesz
(1956) effect (see Hewitt, Blake and
Porter, 1973), has beeninterpreted (though
not by Revesz) as follows: the large
control TD50 is due to the exertion of host
immunity; and the effect of the admixed
LI cells is to abrogate immune influences
TABLE II. Results ofParallel Assays of Tumour Cells Wiith or lVithout
Addition of Homologous LI Cells to the Inocula
Tumour
CBA Leukaemia " Th " (2)
WHT Carciinoma "ALT. " (8)
WHT Sq. Carcinoma " D " (9)
WHT Endothelioma II (12)
CBA Sarcoma " F " (14)
WHT Osteosarcoma I (17)
WHT Sq. Carcinoma " G " (19)
CBA Carcinioma " N.T. " (24)
TD50 (cells)
No LI cells (A) With LI cells (B)
1-4 0 7
1-1 1.1
3-2 2-6
14 3
14 5
17 6
16 1-9
407 1-9
490 7
316 3-5
537 5-8
182 11
1096 14
7900 9 5
2600 4
2300 9
Reduction
factor (A/B)
2
1
1 -2
4.7
2 -8
2 8
8 -4
214
70
90
92
17
78
831
650
256
29d48EVIDENCE FOR ACTIVE HOST DEFENCE AGAINST CANCER
recruited to the site of injection, and so
protect the associated viable tumour cells.
We believe that local abrogation of
immunity, by any means, is a very poorly
documented phenomenon. In the present
case, it seems to us that the addition to
the inoculum of material conceived to be
specifically " antigenic " would tend to
enhance the induction of immunity. Evi-
dence against an immunological inter-
pretation of the Revesz effect included
demonstration that the effect of homo-
logous LI cells can be simulated by LI
cells ofan allogeneic tumour (Hewitt et al.,
1973), and by fibrin or brain extract
(Peters and Hewitt, 1974); we have no
reason to suspect that any of these
additives would abrogate any specific
immuine activity conceived to be directed
against the viable tumour cells. The
following experiment, using a system in
which marked allogeneic immunity was
known to be present, yielded results
which contradict the assertion that LI
cells act by abrogating immune responses:
a suspension of foreign (allografted)
tumour cells was assayed with or without
an added preponderance of their homo-
logous LI cells; in both assays all the
tumours which appeared underwent even-
tual regression; however, the addition of
LI cells increased by 100-fold the number
of viable cells required to obtain tem-
porary growths and hastened regression of
the tumours that did appear. As ex-
pected, the additional antigenic material
represented by LI cells did not inhibit,
but enhanced, the exertion of host
immunity.
Reduction of the TD50 for syngeneic-
ally transplanted tumour cells is also
effected by prior exposure ofthe recipients
to sublethal doses of whole body irradia-
tion (WBI). Table III shows the results
ofparallel assays of viable tumour cells in
normal and irradiated recipients. In the
case of all of the 5 tumours examined, the
TD50 was significantly lower in the
irradiated mice. It is true that WBI is a
powerful suppressant of allograft im-
munity; but that is no reason at all to
ascribe all the effects of WBI, including
that shown in Table III, to immuno-
suppression. The systemic effects of
WBI are severe and protean; the doses of
WBI we have used may be expected to
kill about 95% of the proliferating cells in
the body, and the expression of this
damage results in flooding of the system
with the products of this massive destruc-
tion, from which considerable secondary
effects are to be expected. However,
since repopulation of the depleted cell
populations is known to occur, such
secondary effects would be of limited
duration. Peters (1975), using our CBA
Carcinoma " N.T. " system, has shown
that CBA recipients having sustained
immunosuppression induced by thymec-
tomy and exposure to WBI several
months previously to their use in an assay
of this tumour, yield a TD50 not signi-
ficantly different from that given byintact
recipients. Evidence of the persistence
and intensity of the immunosuppression
was given by Peters' demonstration that
similarly treated CBA mice were as fully
receptive of allografted tumour cells (of
WHT Sq. Carcinoma " G ") as isogeneic
WHT mice. This immaculate evidence
TABLE III.-Results ofParallel Assays ofTumour Cells in Normal and WBI Mice
Tumour
CBA Sarcoma " F " (14)
WHT Osteosarcoma I (17)
WHT Sq. Carcinoma " G " (19)
CBA Carcinoma " N.T. " (24)
WHT Osteosarcoma II (27)
TD50 (cells)
Normal mice (A) WBI mice (B)
81
182
1096
2900
7900
3000
13,200
6
6-6
347
100
64
15
3090
Reduction
factor (A/B)
13 -5
27-6
3 -2
29
123
200
4-3
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clearly indicates that the reduction of
TD50 observed in WBI mice is due to
effects of the irradiation which are quite
distinct from immunosuppression.
We conclude from the evidence given
in this section that the high TD50 values
obtained for many tumours are not to be
taken as signifying their immunogenicity.
We support this conclusion by extensive
evidence that none ofthe many influences
which reduce these high values are to be
described as immunosuppressive.
We would observe here that we cannot
at all reconcile the range of TD50 values
shown in Table I with an assertion of
Southam (1968), that the minimum num-
ber of " living " tumour cells required for
successful transplantation is between 104
and 106, and that this range applies to
autografts, isografts, allografts and xeno-
grafts.
Assay data as evidence ofthe homogeneity of
tumour recipients
As described previously, our assays of
solidtumourcellsuspensionshave involved
the injection ofa selected series ofdilutions
into groups of 4 or more mice, each
receiving 4 s.c. injections. With the
largest mean cell number per site, 100%
ofthe sites are expected to grow tumours;
groups of mice receiving progressively
smaller numbers of cells yield a falling
percentage of takes. If the mice used for
assay included individuals having an
atypical systemic resistance to the tumour,
we should expect to find occasional
uniformly injected groups in which one
mouse had 0/4 takes while all its fellows
had 4/4 takes; a review of our records of
280 assays of various tumours revealed
not a single instance ofsuch a coincidence.
What is not uncommonly observed is the
coincidence of a 0/4 and a 4/4 mouse
within a group in which the other mice
had 1 to 3 tumours in their injected sites;
a certain probability of this occurrence is
to be expected near the end-point of an
assay, even when the mice are assumed to
be homogeneous in their receptivity;
indeed, the frequency of such 0/4: 4/4
coincidence would be greatest in groups
having an overall incidence of 50% takes.
Following this consideration, we analysed
the records of the 280 assays, comprising
data for 8 different tumours and 1400
uniformly injected groups, and found 23
groups in which the 0/4 4/4 coincidence
had occurred; the overall incidence of
tumours was determined in these groups,
and the values were found to lie in the
narrow range 30% to 67%; the mean
overall incidence was 50%. Thus, analy-
sis of this very large volume of data
revealed no evidence that 0/4 mice were
occurring with a frequency that suggested
they represented individuals with aberrant
systemic " resistance ". There was evi-
dently no suggestion of genetic divergence
among the experimental mice in respect of
their compatibility with these tumours.
FAILURE OF ATTEMPTS TO IMMUNIZE MICE
AGAINST ISOGENEICALLY TRANSPLANTED
TUMOURS OF SPONTANEOUS ORIGIN
A need to identify and quantitate any
possible contribution of host immune
influences to the results of our radio-
biological experiments encouraged us to
submit a proportion of our tumour
systems to formal tests for tumour immu-
nogenicity. We emphasize that the indi-
cation for such examination was most
often the emergence ofunexpected findings
which might be given an immunological
interpretation. For example, WHT
Ascites Leukaemia I (3) yielded a much
higher TD50 by s.c. assay than by i.p.
assay.
Many ",immunizing " techniques have
been recommended and as many have
been condemned as inadequate. We have
used multiple injections of LI homologous
tumour cells; induction of immunity has
been sought by the performance ofparallel
assays of viable tumour cells in treated
and normal mice; the pattern of these
assays permitted comparison of tumour
incidence at 4 or 5 levels of challenge.
Potentiating adjuvants have not been
used because they could have complicated
our findings; we have referred in previous
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sections to numerous minor influences
which can reduce the TD50; a similar
nonspecific effect exerted by an adjuvant
could conceal the small rise in TD50
which we sought to reveal. " Immuniza-
tion" by growth and ablation of tumour
entails a considerable risk ofloss oftreated
animals (by metastasis) before the obser-
vation period required for the assay has
elapsed. Indeed, we suggest that this
hazard is more likely to be avoided, and
the experiment completed, in the case of
tumours that are immunogenic and have
their metastases suppressed--which may
explain the superiority claimed for this
technique. However, growth and surgical
ablation ofsome ofour tumours have been
undertaken in the course of our studies of
metastasis: our observation ofa frequency
oflocal recurrence or metastasis after such
treatment is evidence of its failure to
induce resistance in those systems.
Suspensions of tumour cells to be used
for putative immunization have been
prepared by our usual technique; the cells
are killed by exposure to 8000-9000 rad
60Co y-rays. In a great many experiments
with a variety of tumours we have
injected large doses of LI tumour cells
into isogeneic mice and have observed
them for one year: none have grown
tumours. Since the dose ofradiation used
does not significantly inactivate viruses,
the long period of observation of these
mice permits us to exclude subcellular
transmissibility of the tumours used.
Table IV shows for 7 of our tumours
the results of parallel assays of tumour
cells in normal mice and in mice which had
been injected s.c. or i.p. with 2 approxi-
mately equal doses of LI cells given at
specified intervals before challenge with
viable cells. In not a single case was the
TD50 higher in treated than in control
mice; indeed, " immunization " usually
decreased the TD50 by a factor of about
3 0.
The doses of LI cells given depended
on the yield of cells that could be obtained
but in terms of total dose of LI cells per
unit body weight, the doses we gave
exceeded the doses commonly given clinic-
ally in " immunotherapy " trials. For
example, in the case of WHT Ascites
Leukaemia I (3) the total dose of LI cells
was equivalent to clinical administration
of 40 g of sterilized solid tumour; the
minimum dose we used was equivalent to
about 2-0 g (>109 cells).
We reject a suggestion that the reduc-
tion of TD50 we usually observed in
" immunized " mice signifies " immuno-
logical enhancement ": the antigens con-
cerned in enhancing phenomena are pri-
marily alloantigens and not tumour
specific antigens (Snell, 1970).
MISCELLANEOUS OBSERVATIONS
CONCERNING THE NON-IMMUNOGENICITY
OF TUMOURS OF SPONTANEOUS ORIGIN
The experiments to be reported in this
section were not necessarily undertaken to
examine a suspicion of immunogenicity in
the systems used. Nevertheless, they
TABLE IV.-Results ofParallel Assays of Tumour Cells in Normal Mice and
Mice Putatively " Immunized " with Homologous LI Cells
TD50 (cells)
. A
Total LI
Serial cells Intervals*
Tumour passage (x 10-6) (days)
CBA Sq. Carcinoma " D " (9) 82 1-3 18/11
289 1-5 15/8
WHT Fibrosarcoma (10) 123 3-1 14/7
CBA Sq. Carcinoma I (13) 61 1-3 15/8
WHT Asc. Leukaemia I (3) 140 13 16/10
CBA Fibrosarcoma (18) 208 3-2 19/13
CBA Carcinoma " N.T. " (24) 30 0-6 17/10
WHT Carcinoma " N.-C. " (20) 19 0 7 19/12
* Times before challenge, of 1st and 2nd doses of LI cells.
" Immu-
Normal nized "
mice (A) mice (B)
10
25
17
30
195
560
7900
1300
10
10
5
5
89
190
2400
480
Reduction
factor
(A/B)
1
2 -5
3 -4
6
2 -2
3
3 3
2 -7
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TABLE V.-Comparative TD50 Valuesfor Assay of Tumours in F1 Mice and
Syngeneic Mice
Tumour
CBA Leukaemia " Th " (2)
WHT Carcinoma " M.T. " (8)
* Data from Table I.
F1 Cross
CBA x Albino
WHT x CBA
TDr0 (cells)
Hybrid mice Syngeneic mice*
7-6 (0-71-2-8)
> 1000 (4*8-23)
contribute valuable evidence in support of
our contention that our tumours are not
immunogenic. It is important to state
that we have omitted no observations
which go against our contention.
Assay of tumours in F1 hybrids
From our failure to demonstrate eleva-
tion of the TD50 in " immunized " mice
(Table IV) we asserted that the tumours
used were not immunogenic. The asser-
tion requires demonstration that the TD50
doesreflectminorhistocompatibility differ-
ences in a transplant system. Such a
minor difference prevails when a tumour
of origin in a homozygous strain is
transplanted to an F1 hybrid between the
strain of origin and any foreign strain.
The incompatibility is minor because
failures to take, or regressions, do not
generally occur; indeed, many investi-
gators regularly use F1 hybrids in their
tumour studies for logistic convenience.
Table V shows the results of assays of 2 of
our tumours in F1 hybrids having one
parent of the strain of origin. Although
syngeneic preference was more evident in
the case of the carcinoma, in both cases
the TD50 is higher in the F1 hybrids than
in isogeneic mice. Snell (1958) success-
fully used immunization with normal
tissue cells followed by tumour cell assays
to detect weak histocompatibility differ-
ences imposed by small specified genetic
differences between mouse strains. We
conclude that our failure to demonstrate
immunogenicity by our " immunization "
attempts cannot be ascribed to insensi-
tivity of the challenge assay.
We would add here that F1 hybrid
mice are not uncommonly used as reci-
pients in tumour studies given tumour
immunological significance. It is clear
that such systems may entail artefactual
immunity in the form of allogeneic inhibi-
tion (i.e. the converse of syngeneic pre-
ference).
Failure to demonstrate an effect on isogeneic
tumour transplants ofsimultaneous exertion
by the hosts ofinduced nonspecific immunity
Many experimental studies and clinical
trials have been undertaken which proceed
from a hypothesis that nonspecific stimu-
lation of the immunological resources of
the host may restrain the growth or induce
the regression of autochthonous tumours
that have previously progressed in the
host (see Currie, 1974). It seemed to us
that an experiment designed to maximize
the opportunity for demonstration of such
an effect would ensure that: (i) the tumour
cells would be exposed to any immune
influence while they were few in number
and fully accessible-soon after their
injection; (ii) any influence on the cells
would be evaluable quantitatively; anid
(iii) the type of immunity to be non-
specifically stimulated would be cell
mediated. Accordingly, the following
experiment was carried out.
Half of a group of 40 CBA mice were
immunised by s.c. injection into the nape
of 2 doses of viable cells of the foreign
tumour, WHT Carcinoma " M.T. " (8);
the total inoculum, of 1*75 X 106 cells,
gave rise to moderate-sized allograft
tumours which later began to regress.
The immunized and untreated mice were
used 11 days after the second immunising
injection as recipients in parallel assays of
a suspension of viable cells of CBA
Carcinoma " N.T. " (24). A mouse in any
group in the assays received 4 ventral s.c.
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inocula containing the same specified
number of CBA tumour cells; however, in
all groups of both assays, the 2 inocula on
the left side of a mouse contained CBA
tumour cells only, whereas the 2 inocula on
the right side contained the same number
of CBA tumour cells mixed with 105 LI
cells ofthe foreign (WHT) carcinoma cells.
Thus, the immunized and unimmunized
mice provided data for 4 simultaneous
assays, giving TD50 values as shown in
Table VI. It is seen that, in the un-
immunized mice, CBA tumour cells alone
gave a typical TD50 value for this tumour;
the addition of WHT tumour cells to the
inocula significantly reduced the TD50 (by
a factor of 14). In the immunized mice,
the TD50 for CBA tumour cells alone was
not significantly different from that in the
unimmunized mice; the addition of WHT
cells to the inocula again reduced the
TD50, but by a smaller factor, of 4.
It is evident that involvement of the
recipients in reactivity against the foreign
tumour did not increase the TD50, even
when the antigenic material wasintimately
mixed with the isogeneic tumour cells.
Molomut et al. (1955), in a rather
similar experiment, also failed to show any
effect on tumour take or growth ofexertion
of an allergic inflammatory response at the
site ofthe inoculum. Intheirexperiments,
the antigen used to immunize, and added
to the inocula of tumour cells, was
ovalbumin. They used 2 tumours which
were both chemically induced and also
allografted, so that in their case the
nonspecific allergic response had failed
even to stimulate an existing level of
immunogenicity.
TABLE VI.--TD50 Values for Cells of
CBA C(arcinoma " N.T. " Assayed with
or without Admixed LI WHT Tumour
Cells in CBA Mice Immunized or Not
Inmunized against the WHT Tumour
RAecipienlts
Not immunizedI
Immunize(d
WHT cells in inocula
No Yes
7200 510
6500 1700
Thus, our experiment provided no
support whatever for the hypothesis
underlying a technique of " immuno-
therapy " that has been, and continues to
be, widely employed in clinical trials. It is
commonly insisted that such clinical
therapy is expected to influence only
small residual populations oftumour cells:
this requirement was simulated by the
limited andgraded inocula of tumour cells
used in our assays.
Effect of admixed bacteria on tumour
growth from a limited inoculum of tumour
cells
Live or killed pathogenic bacteria give
rise to an acute inflammatory response
confined initially to a site of subcutaneous
injection. The following experiments ex-
amine the effect on tumour take frequency
from limited inocula of isogeneic tumour
cells of their early involvement in such
acute inflammatory response. In 3 separ-
ate experiments, approximately 300 viable
cells of CBA Carcinoma " N.T. " (24) were
injected s.c. in multiple sites into 2 groups
of mice; in one group, the tumour cells
were injected alone and in the other they
were mixed with an equal volume of a
dense suspension of bacteria harvested
from confluent growths on blood-agar
plates. The 3 experiments were distin-
guished by the different bacterial sus-
pensions used. In the case both of partly
viable and ofheat-killedcoagulase-positive
Staphylococcus aureus, temporaryabscesses
were produced at the injection sites
between 5 and 13 days after injection.
From the results of these experiments
(Table VII) it is seen that in all cases the
additive greatly increased the frequency
of tumours. It is evident that tumour
growth was not inhibited by the intensive
nonspecific systemic immunostimulation
or by local involvement ofthe tumour cells
in the pyogenic response or its sequelae.
It is appreciated, however, that this type
ofimmune response is not at all character-
istic ofthat mounted against foreign tissue
cells.
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TABLE VII.-The Effect of Bacterial Addi-
tives on the Tumour-take Frequency of
Small Inocula ofCells of(BA Carcinoma
"N.T."
Tumours/sites
injected
No. of , A_ ,
tumour Bacterial No With
cells additive additive additive
250 Staph. aureus. 0/48 34/44
(part viable)*
300 Staph. aureus. 0/46 30/44
(heat-killed)
360 E. colt 0/48 47/48
(heat-killed)
* This preparation was exposed to heat treatment
intended to sterilize it (60°C x 1 h), but some
organisms were found to have survived.
Failure to inhibit the isogeneic transplanta-
tion of leukaemia cells by their admixture
with a massive preponderance ofspleen cells
from specifically " hyperimmunized" mice
The experiment to be described here
was undertaken duringattempts toexplain
anomalous data concerning the radio-
sensitivity of leukaemia cells irradiated in
vivo in the infiltrated spleens of leukaemic
mice. The results obtained are very
significant within the context of this
section.
A number of CBA mice each received
i.p. a total dose of 2-4 x 107 LI cells ofthe
syngeneic Leukaemia "S1 " I (4) given in
4 doses at about weekly intervals. One
week after the final dose, the spleens ofthe
treated mice (which were not enlarged)
were pooled and macerated to yield a
dense suspension of(mainly) lymphocytes.
Viable leukaemia " SI " cells, with or
without admixture with the " hyper-
immune " spleen cells were then assayed
in parallel in normal CBA mice. The
TD50 values obtained were 1.1 cells
without added spleen cells, and 3*5 cells
with spleen cells. In the latter assay,
at the end-point, each leukaemia cell
was in intimate mixture with a prepon-
derance of 0 5 x 106 spleen cells. Not
only are the TD,50 values not significantly
different, but mice receiving equal
numbers of leukaemia cells in the 2
assays became sick after almost identical
latent periods. It is clear that the spleen
cells from " hyperimmunized " mice had
exerted no cellkilling orgrowthrestraining
effect on the very small number of leu-
kaemia cells with which they were mixed.
It should be added that each mouse in the
assay of the mixed cell population had
received 2 x 106 splenic lymphocytes;
and the conditions ofthe experiment were
such that any immune properties that had
been generated in them would have been
adopted by the recipients in the assay
(Mitchison, 1953). Thus, this extremely
sensitive technique failed to give any
indicationwhateverthatintensive " hyper-
immunization " had conferred any specific
or nonspecific immune properties on the
cells donated, whether these were to act by
direct contact with the target cells or after
their systemic distribution. It is difficult
to believe, in the light of this experiment,
that the scanty infiltration oflymphocytes
found histologically round some clinical
tumours are exerting the tumour restraint
that has been ascribed to them by
innumerable authors during the last sixty
or more years (see Sutherland, 1960).
Comparative growthofaspontaneous tumour
as an autograft in the mouse oforigin and as
an isograft
Owing to the relatively infrequent
occurrence ofspontaneous tumours in low-
cancer strain mice, the opportunity to
compare auto- and isografts at the first
passage rarely arises or is taken. Obser-
vations made at this stage ofa malignancy
are of special importance because it is
commonly suggested that serial trans-
plantation may be associated with loss of
certain immunological or other character-
istics which are peculiar to the original
host-tumour relationship.
An ex-breeder CBA female aged 14
months was seen to have an ulcerated
6 x 2 mm tumour plaqueintheabdominal
skin. This was observed over a period of
about 70 days, during which it grew slowly
andprogressively; atthistime the adjacent
inguinal node was found to be enlarged.
The node and the primary tumour were
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radically excised under ether anaesthesia.
Thenode, whichwasabout 5 mm diameter,
was cut into equal quadrants; one was
autotransplanted into a subcutaneous
pocket prepared in the flank of the donor
opposite to that of the site of tumour
excision; another was similarly trans-
planted to a female CBA taken at random
from the stock colony; the remaining
quadrants were used for histological study.
At the time of grafting it will be appre-
ciated that the donor-recipient was dis-
tinguished from the normal recipient in
having had several months' contact with
the malignancy arising in it; it was there-
fore long exposed to any immunizing
potentiality of the tumour. Observation
of the grafts in the 2 hosts showed that
both gave rise to just palpable nodules on
the same day and subsequently grew at
indistinguishable rates.
On the same day as the above grafts
were made, a cell suspension was prepared
from the primary tumour and assayed in
CBA mice: the TD50 was exceptionally
high ( > 11,000 cells), but this high value
was corroborated by a later assay done at
the 13th passage. The tumour appears in
Table I as CBA Sq. Carcinoma II (26).
Our conclusion from these unusual
observations is that prolonged growth of
the carcinoma in the mouse of origin was
not associated with development of any
change in the host that was manifested by
a resistance to regrafting relative to the
receptivity of an isogeneic unconditioned
animal.
Immunological significance of experiiments
in lymnphnodal metastasis
In the course of our above studies we
have had occasion to transplant iso-
geneically whole regional lymph nodes
draining transplanted tumours of sponta-
neous origin. In a previous publication
(Hewitt and Blake, 1975) we reported
that, in the case of WHT Sq. Carcinoma
" ID " (9), about 400o of such transplanted
nodes gave rise to tumours. We submitted
evidence to show that the node transplants
17
were disclosing the presence in the node of
a small number oftumour cells wAhich were
passing through it, very few of which
would be destined to give rise to a pro-
gressive nodal metastasis if left in situ in
tumour-excised mice. Wte have now con-
firmed in a variety of further systems that
regional node transplants commonly yield
tumours. These data are to be reported in
detail elsewhere but we can summarize
these results here by referring to tumours
by their serial numbers as given in Table I
and giving the percentages of trans-
planted nodes which yielded tumours: (9)
37; (18) 25; (19) 27; (24) 17; (20) 95; (26)
60. Of incidental interest is that the 2
highest percentages of positive node trans-
plants were given by tumours having large
TD50 values.
In experiments with WiHT Sq. Carci-
noma " ) " (9) we found also that the
frequency of tumours from transplanted
nodes was not significantly less for auto-
transplants than for isotransplants.
The above findings have a considerable
implication in the context of tumour
immunology. They show that a small
number of tumour cells are not restrained
in their potential for growth by prolonged
contact with an overwhelming prepon-
derance of lymphocytes which have been
"sensitized " in the donor mouse by the
growth of tumour in the region they drain.
This contact is retained in the trans-
plantee; moreover, because the node is
transplanted isogeneically, any immune
faculties in these node cells will be adopted
by the new host (Mitchison, 1953).
The fact that nodes vary in their
ability to give rise to tumours is reasonably
explained by whether or not there happens
to be a sufficient number of tumour cells
in a node at the time ofits transplantation.
The alternative explanation, that some
mice are exerting an immune influence
and others not, proclaiims genetic hetero-
geneity among the hosts; but that would
be clear evidence ofartefactual immunity:
specific tumour immunity as conceived
implies that the tumour is uniformly
immutnogeniic in all the mice that are
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nominally syngeneic with the mouse of
origin.
DISCUSSION
Most tumour immunology experiments
using animal tumour systems are explicitly
or tendentiously aimed at providing a
foundation for clinical immunotherapy;
the intention is either to justify its long
historical practice, which has been recently
reviewed by Currie (1972) or to refine the
methods currently used. The endeavour
is sustained by one or other of 2 hypo-
theses: that such therapy can induce
immunogenicity in a clinical tumour or
that it can potentiate an existing level of
immunogenicity which is insufficient to
assist control of the disease. The results
of our studies, using exclusively tumours
of spontaneous origin, provide no support
for either hypothesis. In particular, we
refer to our demonstration that putative
" immunization " with homologous LI
tumour cells always increased, never
reduced, the capacity of isogeneic hosts to
support tumour growth from very small
inocula of viable tumour cells (Table IV).
The technique of immunization we em-
ployed, whilst it met the requirements of
our experiments and, incidentally, simu-
lated the commonest form of clinical
" immunotherapy ", may well be deemed
to be suboptimal. However, our systems
have always been made freely available to
tumour immunologists for more intensive
study by the application of other methods
of enhancing or measuring an immune
response. In only one of the several
instances in which advantage was taken
was any evidence of an immune response
obtained. The exception was in respect of
one of our leukaemia lines, for which
evidence of immunogenicity has been
reported (Smith and Scott, 1972); however,
this finding can be excluded from our
present context because it was disclosed
that the immunogenicity was observed
only in graftees which were of a substrain
different from that in which the leukaemia
arose; the demonstration of immunity
clearly depended upon the introduction of
an artefactual condition.
We are aware that our uniformly
negative evidence has to be set beside a
very large volume of reported data from
animal tumour studies in which an immune
response against tumour has been readily
demonstrated. We assert that the pecu-
liarity of our extensive experience is attri-
butable to the category of tumour origin
which we have exclusively used; and that
the positive evidence with which our own
conflicts has been obtained almost entirely
from animal systems entailing artefactual
immunity, as described in ourintroductory
paragraphs.
Tumour systems entailing artefactual
immunity do provide a valuable and
proper facility for studying phenomena
acknowledged to be immunological. How-
ever, we suggest that a much more dis-
criminating choice of animal tumour
system is obligatory if it is to serve as a
model of the common forms of clinical
cancer, information from which is intended
to improve our understanding of the
human disease or to provide a prescription
for innovations into clinical therapy.
Encouraged by the prevailing demand for
closer collaboration between workers inthe
research laboratory and those in the clinic,
authors ofanimal dataincreasinglyindulge
the inclination to draw direct clinical
implications from their findings. The
indulgence imposes a heavier responsi-
bility than is often realized, for those who
may act clinically upon their advice are
commonly, and quite excusably, deficient
in the knowledge required to assess the
validity of an animal model and the
propriety of the analogies drawn, and this
is a defect of communication which cannot
be excluded even where a clinician acts
upon his own findings from animal
experiments. In Table VIII we cite a
small sample of the papers which have
reported the results of animal tumour
experiments to which clinical significance
was given by the authors by direct clinical
application, by discussion in a clinical
context or by publication in a journal of
predominantly clinical readership. Several
of these papers have been very widely
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TABLE VIII.-Status of Transplanted Animal Tumour Systems Used in Experiments
Discussed in Relation to Immunology of Clinical Cancer
Tumour
Leukaemia L 1210
Leukaemia E Y KI
Leukaemia, Rauscher
Sarcoma 180
Sarcoma 1
Walker 256
Lymphosarcoma
6C3HED (Gardner)
BLMC Fibrosarcoma
Fibrosarcoma MC-42
Fibrosarcoma MC-43
Fibrosarcoma
Lymphosarcoma
6C3HED (Gardner)
Fibrosarcoma
Leukaemia LSTRA
Leukaemia E 3 G2
Fibrosarcoma MCI
Fibrosarcoma MC6
Origin* (year) Reference
C-I (1948)
V-I (?) -Mathe (1972)
V-I (?) J
AC (19147) Crile (1965)
A (1928) iGardner and Rosen (1967)
C-I (?) j
C-I (1941) Perez et al. (1973)
C-I ( - 1969) Hammond and Rolley (1970)
C-I (?)
C-I (?)
C-I (1964)
C-I (1941)
C-I (?)
V-I (?)
V-I (?)
C-I (?)
C-I (?)
}Simmons and Rios (1973)
Haddow and Alexander (1964)
Powers and Palmer (1967)
Suit et al. (1975)
Pearson et al. (1972)
Amiel and Berardet (1970)
}Currie and Bagshawe (1970)
Clinical context
Immunotherapyt
Analogy for surgical policy
(re node retention)
Discussion
(re node retention)
Discussion
(re node retention)
Discussion
(re node retention)
Discussion
(use of BCG)
Lancet (Radiotherapy + imm.)
Discussion
(Radiotherapy + imm.)
Discussion (immunotherapy)
Discussion (immunotherapy)
Discussion (immunotherapy)
Br. med. J.
(immunotherapy)
* C-I = chemically-induced; V-I = virus-induced; A = allograft.
t " These experimental results form the basis of the possible clinical application of active immuno- therapy. " (Mathe, 1972.)
quoted in support of clinical intentions;
yet in no case were the data obtained
from an isogeneically transplanted tumour
of spontaneous origin; we are not aware
that these authors have been able to
confirm their findings using more eligible
experimental systems.
Many of the terms used to describe an
animal tumour system, though correct,
can convey unwarranted confidence in its
eligibility as a model-at least to the
uninitiated: "primary ", "autochtho-
nous" and " isogeneically transplanted"
are terms which exclude only frank
allografted tumours; they do not exclude
systems entailing artefactual immunity
attributable to their mode of induction or
to genetic diversity associated with a
substrain difference between the animal in
which a tumour arose and the graftees
used. The term " spontaneous " is com-
monly, and quite incorrectly, used to
describe the characteristic malignancies
arising in high leukaemia or mammary
tumour mouse strains such as AKR or
C3H respectively; these malignancies are,
of course, induced by vertically trans-
mitted exogeneous viruses, albeit in im-
munologically tolerant hosts. We suggest
that " spontaneous " be reserved to de-
scribe tumours arising in circumstances
where no oncogenic agency has been
proved to be involved; the category
deserves distinction for the immuno-
logical peculiarity we have described. To
disallow all usage of " spontaneous " on
metaphysical grounds that all events have
causes would be merely to invite the
neologism we should then require.
Enchantment of experimenters with
the general theory of tumour immunity
has, in our view, led to the too facile
attachment of immunological interpreta-
tions to complex manifestations of cancer
biology deserving of much broader con-
sideration. The effect has been to treat
such interpretations as final rather than
provisional and so to abate the scepticism
that inspires further investigation. We
have already referred to the persistence of
the theory that the facilitation of tumour
graft acceptance effected by prior WBI of
recipients is solely due to immunosup-
pression; yet it has been shown by van
den Brenk, Sharpington and Orton (1973)
that, even in allogeneic systems, several
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non-immunological factors contribute to
this effect of WBI. The appealing
immunological connotations attaching
historically to BCG have, likewise,
encouraged an exclusively immunological
interpretation of its effects on tumour
growth. The severity of its systemic
effects, the peculiar technical conditions
required for demonstration of its effect on
tumour growth, and the fact that such
effects can be inhibiting or enhancing
(Baldwin and Pimm, 1973) invite more
liberal interpretation. Caution is equally
required in interpreting the apparently
favourable effect of BCG in clinical
" immunotherapy " (Crowther etal., 1973).
Demonstration of clinical advantage does
not necessarily ratify the theory insti-
gating a trial.
We suspect that the almost exclusive
resort oftumour immunologists to chemic-
ally induced, virus-induced or allografted
tumours is calculated to eke out evidence
supporting the general theory of effective
tumour immunogenicity which otherwise
might fail to attract the very large
attention it receives. We venture to
suggest that expansion of an already vast
volume ofliterature would be considerably
restrained ifpublication ofpapers drawing
clinical implications from animal experi-
ments in this field were made conditional
upon the use of tumour systems free from
the more obvious stigmata of artefactual
immunity.
Almost half a century ago the perti-
nence of the contemporary data from
animal tumour studies was questioned in
the more robust and critical style which
was then permissible (Woglom, 1929;
Mottram, 1930), but investigators were
at that time severely restricted in respect
of the animal tumours and related tech-
nical facilities available to them. Whereas
the deprivations of the past can only be
regretted, the motivations influencing free
choice at the present time deserve to be
questioned.
We are grateful to Dr H. A. S. van den
Brenk for the benefit of his extensive
clinical and laboratory experience in
many discussions, and for his review ofthe
script, to Miss Carol Dear and Mrs
Patricia Whitman for assistance in the
care of animals, and to Mrs Karen Jepson
for preparation of the manuscript. Dr
D. C. Roberts and the Registry and
Information Service for Experimental
Tumours (Imperial Cancer ResearchFund)
provided indispensable assistance in trac-
ing the origin of the tumours we have
directly or indirectly referred to.
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